CTLA4 and melanoma: Since anti-CTLA-4 antibody (ipilimumab) was approved as therapy for the treatment of melanoma patients [46], we addressed the question whether the combination of ipilimumab with our improved DC vaccine could enhance the anti-tumour effects in a patient who initially did not respond to the antibody therapy.